Holen Sie sich die Stockscreener-App
13.56
0.84%
-0.115
Schlusskurs vom Vortag:
$13.68
Offen:
$13.57
24-Stunden-Volumen:
186.44K
Relative Volume:
0.61
Marktkapitalisierung:
$453.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-8.6661
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
+11.23%
1M Leistung:
+22.76%
6M Leistung:
+26.19%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.18
$14.20
1-Wochen-Bereich:
$11.56
$14.20
52-Wochen-Spanne:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
13.56 | 391.07M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.46 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
589.03 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.53 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
Is MBX Biosciences Inc. a good long term investmentExtraordinary market timing - Autocar Professional
What analysts say about MBX Biosciences Inc. stockJaw-dropping returns - Autocar Professional
Oppenheimer reiterates Outperform rating on MBX Biosciences stock ahead of Phase 2 data - Investing.com India
What drives MBX Biosciences Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com
Why MBX Biosciences Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser
MBX Biosciences Inc. Stock Analysis and ForecastUnmatched market gains - printweek.in
MBX Biosciences (NYSE:MBX) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
MBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of “Buy” from Analysts - Defense World
MBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at Oppenheimer - Defense World
Is MBX Biosciences Inc. stock a good hedge against inflationLow Risk Stock Strategies - Newser
Is MBX Biosciences Inc. stock overhyped or has real potentialFree Investment Community - Newser
MBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Oppenheimer Initiates Coverage on MBX Biosciences with Outperform Rating, PT $38 - AInvest
Oppenheimer initiates MBX Biosciences stock with Outperform rating - Investing.com Australia
Oppenheimer initiates MBX Biosciences stock with Outperform rating By Investing.com - Investing.com India
Oppenheimer initiates coverage on MBX Biosciences with 'outperform' - TradingView
MBX Biosciences stock maintains Market Outperform rating at JMP By Investing.com - Investing.com India
MBX Biosciences stock maintains Market Outperform rating at JMP - Investing.com
why mbx biosciences inc. stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
How MBX Biosciences Inc. stock performs during market volatilityProfessional Stock Screener - Newser
What makes MBX Biosciences Inc. stock price move sharplyFree Investment Community - Newser
Insiders Rewarded With US$78k Addition To Investment As MBX Biosciences Stock Hits US$359m - 富途牛牛
MBX Biosciences stock maintains Market Outperform rating at JMP on strong Yorvipath launch - Investing.com
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 3000 Growth Index - MarketScreener
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 2000 Growth Index - MarketScreener
Stifel reiterates buy rating on MBX Biosciences stock ahead of trial - Investing.com India
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - GlobeNewswire
Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating - TipRanks
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.26%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):